ABSTRACT
Background The diagnostic performance of the high-sensitivity troponin T (hs-cTnT) European Society of Cardiology (ESC) 0/1-hour algorithm in sex and race subgroups is unclear, particularly in U.S. Emergency Department (ED) patients.
Methods A pre-planned subgroup analysis of the STOP-CP cohort study was conducted. Participants with 0- and 1-hour hs-cTnT measures (Roche Diagnostics; Basel, Switzerland), prospectively enrolled at eight U.S. EDs from 1/2017-9/2018, were stratified into rule-out, observation, and rule-in zones using the hs-cTnT ESC 0/1 algorithm. The primary outcome was adjudicated 30-day cardiac death or MI. Rates of patient stratification to each ESC 0/1 zone and the proportion with 30-day cardiac death or MI in each zone were compared between subgroups with Fisher’s-exact tests. The negative predictive value (NPV) of the ESC 0/1 rule-out zone for 30-day cardiac death or MI was calculated and compared between subgroups using Fisher’s exact tests.
Results Of the 1422 patients enrolled, 54.2% (770/1422) were male and 58.1% (826/1422) white with a mean age of 57.6 ± 12.8 years. At 30 days, cardiac death or MI occurred in 12.9% (183/1422) of participants. The ESC 0/1-h algorithm ruled-out more women than men [66.9% (436/652) vs 50.0% (385/770); p<0.001] and a similar proportion of white vs non-white patients [59.3% (490/826) vs 55.5% (331/596); p=0.16]. Among patients stratified to the rule-out zone, 30-day cardiac death or MI occurred in 1.1% (5/436) of women vs 2.1% (8/436) of men (p=0.40) and 1.2% (4/331) of non-white patients vs 1.8% (9/490) of white patients (p=0.58). The NPV for 30-day cardiac death or MI was similar among women vs men [98.9% (95%CI 97.3-99.6) vs 97.9% (95%CI 95.9-99.1); p = 0.40] and among white vs non-white patients [98.8% (95%CI 96.9-99.7) vs 98.2% (95%CI 96.5-99.2); p=0.39].
Conclusions The ESC 0/1-h hs-cTnT algorithm ruled-out more women than men, but achieved similar NPV for 30-day cardiac death or MI in all subgroups. NPVs <99% in each subgroup suggests the hs-cTnT ESC 0/1-h algorithm may not be safe for U.S. ED use.
Trial Registration High-Sensitivity Cardiac Troponin T to Optimize Chest Pain Risk Stratification (STOP-CP; ClinicalTrials.gov: NCT02984436; https://clinicaltrials.gov/ct2/show/NCT02984436)
What is Known
The European Society of Cardiology high-sensitivity troponin T (hs-cTnT) 0/1-hour algorithm has been validated as a tool to rule-out myocardial infarction (MI).
Evaluations of its performance differences based on sex and race are limited.
What the Study Adds
In this multisite U.S. cohort study of 1422 adults, the high-sensitivity troponin T (hs-cTnT) ESC 0/1-hour algorithm had a similar NPV in men vs women and white vs non-white patients but did not achieve ≥99% NPV for 30-day cardiac death or MI in any subgroup.
Emergency providers should be aware of the potential limitations of using the ESC 0/1-hour hs-cTnT algorithm for risk stratification because it may not satisfactorily exclude 30-day cardiac death or MI in any subgroup of ED patients (men, women, white patients, or non-white patients) with acute chest pain.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
High-Sensitivity Cardiac Troponin T to Optimize Chest Pain Risk Stratification (STOP-CP; ClinicalTrials.gov: NCT02984436; https://clinicaltrials.gov/ct2/show/NCT02984436)
Funding Statement
Sources of Funding: This investigator-initiated study was funded by Roche Diagnostics. Dr. O?Neill receives funding/support from Cytovale, Wake Forest CTSI, and National Center for the Advancement of Translational Sciences. Dr. Ashburn receives funding from NHLBI (T32HL076132). Dr. Snavely receives funding from Abbott and HRSA (1H2ARH399760100). Dr. Stopyra receives research funding from NCATS/NIH (KL2TR001421), HRSA (H2ARH39976-01-00), Roche Diagnostics, Abbott Laboratories, Pathfast, Genetesis, Cytovale, Forest Devices, Vifor Pharma, and Chiesi Farmaceutici. Dr. Mahler receives funding/support from Roche Diagnostics, Abbott Laboratories, Ortho Clinical Diagnostics, Siemens, Grifols, Pathfast, Quidel, Genetesis, Cytovale, and HRSA (1H2ARH399760100). He is a consultant for Roche, Quidel, Abbott, Genetesis, Inflammatix, Radiometer, and Amgen and the Chief Medical Officer for Impathiq Inc. Dr. Allen receives research funding/support from Roche Diagnostics, Siemens Healthineers and Beckman Coulter. He is a consultant for Roche Diagnostics. Dr. Nowak receives research funding/support from Roche Diagnostics, Beckmann Coulter, Siemens, Abbott Diagnostics, and Ortho Clinical Diagnostics. He is a consultant for Roche Diagnostics, Beckman Coulter, Siemens, Abbott Diagnostics, and Ortho Clinical Diagnostics. Dr Mumma has research support from the NIH (5K08HL130546) and Roche Diagnostics. Dr Christenson is a consultant for and receives funding/support from Roche Diagnostics, Siemens Healthineers, Beckman Coulter Diagnostics, Becton Dickinson and Co, Quidel Corp, and Sphingotec GMBH. Dr. Wilkerson receives research support from Regeneron, Eli Lilly, Cepheid, CoapTech, Global Blood Therapeutics, Novartis, EndPoint Health, Roche, Vapotherm, and Eldon. He has received research support from the National Heart, Lung, and Blood Institute (No. U24HL137907) and the National Institute for Diabetes and Digestive and Kidney Diseases (No. R44DK115325). He has been a contracted author for Elsevier Publishing and Relias Learning LLC. The other authors report no conflicts.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study sites included the University of Florida, Gainesville, Florida; Wake Forest University, Winston Salem, North Carolina; Henry Ford Health System, Detroit, Michigan; University of Maryland St. Joseph Medical Center, Towson, Maryland; University of Maryland Medical Center, Baltimore, Maryland; University of Maryland Baltimore Washington Medical Center, Glen Burnie, Maryland; University of California-Davis, Davis, California; and University of Utah, Salt Lake City, Utah. Institutional review board approval was obtained at all sites.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data
